Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 118

1.

Diagnostic delay in Parkinson's disease caused by PRKN mutations.

Ruiz-Lopez M, Freitas ME, Oliveira LM, Munhoz RP, Fox SH, Rohani M, Rogaeva E, Lang AE, Fasano A.

Parkinsonism Relat Disord. 2019 Jan 10. pii: S1353-8020(19)30010-0. doi: 10.1016/j.parkreldis.2019.01.010. [Epub ahead of print]

PMID:
30692050
2.

Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review.

Seppi K, Ray Chaudhuri K, Coelho M, Fox SH, Katzenschlager R, Perez Lloret S, Weintraub D, Sampaio C; and the collaborators of the Parkinson's Disease Update on Non-Motor Symptoms Study Group on behalf of the Movement Disorders Society Evidence-Based Medicine Committee.

Mov Disord. 2019 Feb;34(2):180-198. doi: 10.1002/mds.27602. Epub 2019 Jan 17. Review. Erratum in: Mov Disord. 2019 May;34(5):765.

PMID:
30653247
3.

Pridopidine, a clinic-ready compound, reduces 3,4-dihydroxyphenylalanine-induced dyskinesia in Parkinsonian macaques.

Johnston TH, Geva M, Steiner L, Orbach A, Papapetropoulos S, Savola JM, Reynolds IJ, Ravenscroft P, Hill M, Fox SH, Brotchie JM, Laufer R, Hayden MR.

Mov Disord. 2019 May;34(5):708-716. doi: 10.1002/mds.27565. Epub 2018 Dec 21.

PMID:
30575996
4.

Th17 lymphocyte spearheads the immune attack in Parkinson's disease: New evidence for neuronal death.

Wagle Shukla A, Fox SH.

Mov Disord. 2018 Oct;33(10):1560. doi: 10.1002/mds.27496. No abstract available.

PMID:
30365216
5.

Educational Needs and Considerations for a Visual Educational Tool to Discuss Parkinson's Disease.

Udow SJ, Hobson DE, Kleiner G, Masellis M, Fox SH, Lang AE, Marras C.

Mov Disord Clin Pract. 2017 Nov 27;5(1):66-74. doi: 10.1002/mdc3.12563. eCollection 2018 Jan-Feb.

6.

Levodopa-induced dyskinesia in Parkinson disease: Current and evolving concepts.

Espay AJ, Morgante F, Merola A, Fasano A, Marsili L, Fox SH, Bezard E, Picconi B, Calabresi P, Lang AE.

Ann Neurol. 2018 Dec;84(6):797-811. doi: 10.1002/ana.25364. Epub 2018 Nov 30. Review.

PMID:
30357892
7.

Viewpoint: Developing drugs for levodopa-induced dyskinesia in PD: Lessons learnt, what does the future hold?

Fox SH, Brotchie JM.

Eur J Neurosci. 2019 Feb;49(3):399-409. doi: 10.1111/ejn.14173. Epub 2018 Nov 15.

PMID:
30269407
8.

Automated assessment of levodopa-induced dyskinesia: Evaluating the responsiveness of video-based features.

Li MH, Mestre TA, Fox SH, Taati B.

Parkinsonism Relat Disord. 2018 Aug;53:42-45. doi: 10.1016/j.parkreldis.2018.04.036. Epub 2018 May 5.

PMID:
29748112
9.

Update in therapeutic strategies for Parkinson's disease.

Kulisevsky J, Oliveira L, Fox SH.

Curr Opin Neurol. 2018 Aug;31(4):439-447. doi: 10.1097/WCO.0000000000000579. Review.

PMID:
29746402
10.

Emotion Detection Deficits and Decreased Empathy in Patients with Alzheimer's Disease and Parkinson's Disease Affect Caregiver Mood and Burden.

Martinez M, Multani N, Anor CJ, Misquitta K, Tang-Wai DF, Keren R, Fox S, Lang AE, Marras C, Tartaglia MC.

Front Aging Neurosci. 2018 Apr 24;10:120. doi: 10.3389/fnagi.2018.00120. eCollection 2018.

11.

International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease.

Fox SH, Katzenschlager R, Lim SY, Barton B, de Bie RMA, Seppi K, Coelho M, Sampaio C; Movement Disorder Society Evidence-Based Medicine Committee.

Mov Disord. 2018 Aug;33(8):1248-1266. doi: 10.1002/mds.27372. Epub 2018 Mar 23. Review. Erratum in: Mov Disord. 2018 Dec;33(12):1992.

PMID:
29570866
12.

Exacerbation of psychosis triggered by a synthetic cannabinoid in a 70-year-old woman with Parkinson disease.

Udow SJ, Freitas ME, Fox SH, Lang AE.

CMAJ. 2018 Jan 15;190(2):E50-E52. doi: 10.1503/cmaj.170361. No abstract available.

13.

Botulinum Toxin Type A for Pain in Advanced Parkinson's Disease.

Bruno V, Freitas ME, Mancini D, Lui JP, Miyasaki J, Fox SH.

Can J Neurol Sci. 2018 Jan;45(1):23-29. doi: 10.1017/cjn.2017.245.

PMID:
29334040
14.

DPI-289, a novel mixed delta opioid agonist / mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson's disease.

Johnston TH, Versi E, Howson PA, Ravenscroft P, Fox SH, Hill MP, Reidenberg BE, Corey R, Brotchie JM.

Neuropharmacology. 2018 Mar 15;131:116-127. doi: 10.1016/j.neuropharm.2017.11.046. Epub 2017 Nov 29.

PMID:
29197517
15.

Automated vision-based analysis of levodopa-induced dyskinesia with deep learning.

Li MH, Mestre TA, Fox SH, Taati B.

Conf Proc IEEE Eng Med Biol Soc. 2017 Jul;2017:3377-3380. doi: 10.1109/EMBC.2017.8037580.

PMID:
29060621
16.

Motor Complications of Dopaminergic Medications in Parkinson's Disease.

Freitas ME, Hess CW, Fox SH.

Semin Neurol. 2017 Apr;37(2):147-157. doi: 10.1055/s-0037-1602423. Epub 2017 May 16. Review.

17.

Serotonergic Approaches in Parkinson's Disease: Translational Perspectives, an Update.

Huot P, Sgambato-Faure V, Fox SH, McCreary AC.

ACS Chem Neurosci. 2017 May 17;8(5):973-986. doi: 10.1021/acschemneuro.6b00440. Epub 2017 May 5. Review.

PMID:
28460160
18.

Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease.

Fox SH, Metman LV, Nutt JG, Brodsky M, Factor SA, Lang AE, Pope LE, Knowles N, Siffert J.

Mov Disord. 2017 Jun;32(6):893-903. doi: 10.1002/mds.26976. Epub 2017 Mar 30.

PMID:
28370447
19.

The Relationship Between Serotonin-2A Receptor and Cognitive Functions in Nondemented Parkinson's Disease Patients with Visual Hallucinations.

Cho SS, Strafella AP, Duff-Canning S, Zurowski M, Vijverman AC, Bruno V, Aquino CC, Criaud M, Rusjan PM, Houle S, Fox SH.

Mov Disord Clin Pract. 2017 Jan 23;4(5):698-709. doi: 10.1002/mdc3.12466. eCollection 2017 Sep-Oct.

20.

Palliative care and Parkinson's disease: Meeting summary and recommendations for clinical research.

Kluger BM, Fox S, Timmons S, Katz M, Galifianakis NB, Subramanian I, Carter JH, Johnson MJ, Richfield EW, Bekelman D, Kutner JS, Miyasaki J.

Parkinsonism Relat Disord. 2017 Apr;37:19-26. doi: 10.1016/j.parkreldis.2017.01.008. Epub 2017 Jan 11. Review.

PMID:
28108265

Supplemental Content

Loading ...
Support Center